Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
myeloproliferative disorders
MeSH D009196 - myeloproliferative disorders
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D001855:
Bone marrow diseases
17 Companies
1 Drug
$
Success rate
D009196:
Myeloproliferative disorders
2 Companies
2 Drugs
$
Success rate
D000750:
Myelophthisic anemia
0 Companies
0 Drugs
Success rate
D004915:
Erythroblastic leukemia acute
0 Companies
0 Drugs
Success rate
D007955:
Leukemoid reaction
0 Companies
0 Drugs
Success rate
D011087:
Polycythemia vera
37 Companies
8 Drugs
$
Success rate
D013922:
Thrombocytosis
13 Companies
3 Drugs
$
Success rate
D015464:
Bcr-abl positive chronic myelogenous leukemia
47 Companies
13 Drugs
$
Success rate
D015467:
Neutrophilic leukemia chronic
1 Company
1 Drug
$
Success rate
D055728:
Primary myelofibrosis
21 Companies
5 Drugs
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Novartis
Ruxolitinib
Jakavi
2012-08-23
$1,541 M
Q2/20-Q2/23
Clinical Trials
Historical Success Rate
Phase 1
76
%
60/79
Phase 2
25
%
20/79
Phase 3
10
%
5/50
Approved:
3
Overall Success rate:
2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Bristol Myers Squibb
Fedratinib
Novartis
Ruxolitinib
,
Sti571
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use